Top Story Today
Medicare Bets Billions That $50 Weight-Loss Drugs Will Pay for Themselves
For the first time ever, Medicare is covering weight-loss drugs. The new GLP-1 Bridge pilot, launched July 1, offers seniors Wegovy, Zepbound, and Lilly's oral pill Foundayo for a flat $50 per month, down from list prices north of $1,000. The program runs through December 2027, targets beneficiaries with a BMI of 27 or above (plus qualifying conditions), and excludes patients who already have coverage for GLP-1s through other channels. Wall Street's split on the winners: Lilly is trading near all-time highs above $1,100, while Novo Nordisk sits around $48 with projected sales declines this year.
Why it matters: Two-thirds of Medicare beneficiaries are overweight or obese, so even a temporary pilot could reshape the economics of the entire obesity drug market. The bigger question: can 18 months of data justify permanent coverage, or does the program end with millions of seniors losing access to drugs that only work as long as you take them?
Read more →FDA Approvals
The Most Powerful Antibiotic Class Just Escaped the Hospital
Until now, carbapenems (medicine's last-resort antibiotics) required an IV and a hospital bed in the U.S. Not anymore. The FDA approved GSK's Utebzi, the first-ever oral carbapenem, for complicated UTIs. In a 1,690-patient trial, the pill matched IV imipenem almost exactly, hitting a 58.5% composite cure rate. With over 3 million complicated UTI cases annually in the U.S., the approval could shift serious infections from inpatient to outpatient care, if stewardship keeps overuse in check.
Read more →Gene Therapy for Toddlers With Sickle Cell Is Now Real
The FDA cleared Vertex's CRISPR-based CASGEVY for children as young as two with sickle cell disease, making it the first gene therapy approved for toddlers with sickle cell disease and transfusion-dependent β-thalassemia. The catch: treatment costs roughly $3 million per patient, requires months of hospitalization and harsh chemotherapy, and uptake has been limited so far.
Read more →A Cell Therapy That Makes Bone Marrow Transplants Dramatically Safer
Orca Bio's Tregzi earned FDA approval after a pivotal trial showed 78% of blood cancer patients survived a year without serious graft-versus-host disease, compared to just 38% with standard transplants. The therapy sorts donor cells at the single-cell level, sending in immune peacekeepers before the cancer-fighting troops arrive. Transplant-related deaths dropped from 13% to 3.4%.
Read more →First New Sunscreen Ingredient in 25 Years Finally Clears the FDA
The FDA approved bemotrizinol, a broad-spectrum UV filter already used globally, as the first new OTC sunscreen active ingredient since the late 1990s. The approval breaks a decades-long regulatory freeze and could open the door for other modern UV filters that have been stuck in limbo.
STAT News →Deals and Dollars
AstraZeneca Pays Up to $1.77B for Kidney Drugs That Don't Exist Yet
AstraZeneca signed its fourth major deal with China's CSPC, this time paying up to $1.77 billion for two preclinical kidney disease molecules. Only $30 million goes out the door now. The real purchase: CSPC's siRNA delivery platform that can target kidneys, an organ most genetic medicines still can't reach.
Read more →Takeda Bets $600M on AI-Designed Drugs From Insilico Medicine
Takeda is paying Insilico Medicine up to $600 million (with $60 million upfront) to let an AI platform design its next drug candidates. Insilico now counts Lilly, Sanofi, and SK Biopharma among its partners, with cumulative deal value exceeding $6 billion. AI drug discovery deals hit $43.4 billion in potential value across 114 deals in 2025 alone.
Read more →A VC-Backed Startup Just Wrote a $2.2B Check for an Alzheimer's Drug
Danish startup QuantumCell, backed by Forbion, Novo Holdings, and Lundbeckfond, licensed AlzeCure's Alzheimer's candidate ACD856 in a deal worth over $2.2 billion. Only $12 million is upfront. It's one of the largest VC-backed neurodegeneration bets ever, arriving as Alzheimer's deal activity has surged roughly 780% since the first anti-amyloid approvals.
Read more →$180M Says IPF Is Biotech's Most Overlooked Opportunity
Celea Therapeutics raised $180 million from RA Capital, Leaps by Bayer, and a sovereign wealth fund for a single lung fibrosis drug. Deupirfenidone, a deuterated version of pirfenidone, showed a 98.5% probability of beating placebo in Phase 2b. The company plans a bold head-to-head superiority trial against pirfenidone starting this quarter.
Read more →Pipeline Watch
Merck Strikes Out in Alzheimer's. One Shot Left.
Merck killed its Phase 2 trial of MK-1167, an oral Alzheimer's drug that aimed to amplify weakened brain signals, after it failed to show enough efficacy. It's the company's fourth Alzheimer's setback, leaving just one candidate (a tau-targeting antibody called MK-2214) in its pipeline. Wall Street didn't flinch; analysts had already written off Merck's CNS ambitions.
Read more →The FDA Wants to Watch Your Clinical Trial in Real Time
The FDA launched two proof-of-concept studies that stream clinical trial data to regulators live, rather than months after the fact. AstraZeneca's TRAVERSE trial (mantle cell lymphoma) has already transmitted validated real-time signals. If the approach scales, industry projections suggest trial timelines could shrink 20-40%, though cybersecurity and data quality questions remain wide open.
Read more →